nemorubicin

Nemorubicin is a **morpholinyl analogue of doxorubicin**, an anthracycline antineoplastic agent.[2][5][8] It features a methoxymorpholinyl group attached to the 3' position of the sugar moiety, which imparts increased cytotoxicity against multidrug-resistant tumor cells and reduced cardiotoxicity compared to doxorubicin.[1][3][4][7][8] Nemorubicin acts primarily as a DNA-intercalating agent, inhibiting topoisomerase II.[8] It is metabolized by CYP3A enzymes into highly potent cytotoxic metabolites.[8] Preclinically, it demonstrated potent anticancer activity versus hepatocellular carcinoma and other solid tumors.[1] It has been evaluated in phase I/II clinical studies for solid tumors, showing dose-limiting toxicities of neutropenia and severe gastrointestinal symptoms, with no observed clinical responses; its further oral development was discontinued due to excessive toxicity.[3][4][7]

Other names

methoxymorpholinyl doxorubicinMethoxymorpholinyldoxorubicinNemorubicin